[VSsupport]

Ironwood Pharmaceuticals Inc., of Cambridge, and Astellas Pharma Inc., of Tokyo, have entered into a licensing agreement that will give the Japanese pharmaceutical firm exclusive development and commercialization rights to Ironwood’s irritable bowel syndrome drug in several Asian nations.View the full article